Kameron Edwards, | |
2325 Clement Ave Ste A, Alameda, CA 94501-7061 | |
(510) 629-6377 | |
Not Available |
Full Name | Kameron Edwards |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 2325 Clement Ave Ste A, Alameda, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1801395009 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Kameron Edwards, 5826 Occidental St, Emeryville, CA 94608-2328 Ph: (510) 452-7799 | Kameron Edwards, 2325 Clement Ave Ste A, Alameda, CA 94501-7061 Ph: (510) 629-6377 |
News Archive
Alzheimer's disease and schizophrenia are some of the most common brain disorders and have been associated with problems in cells that contain a type of protein, called parvalbumin.
Discovery Laboratories, Inc. has been notified that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 7,863,241 titled "Compositions for Treatment and Prevention of Pulmonary Conditions." The patent provides broad coverage for compositions that employ a combination of certain pulmonary surfactants with a broad array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.
Research conducted at LSU Health New Orleans Neuroscience Center of Excellence reports that a combination of an LSU Health-patented drug and selected DHA derivatives is more effective in protecting brain cells and increasing recovery after stroke than a single drug. The findings are published in Brain Circulation, available here.
Missing out on the recommended seven or more hours of sleep per night could lead to more opportunities to make poorer snacking choices than those made by people who meet shut-eye guidelines, a new study suggests.
Cell Therapeutics, Inc. today announced the launch of PIXUVRI (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
› Verified 3 days ago